| abstract |
REFERRED TO A COMPOUND DERIVED FROM PYRROLOPYRIMIDINE OF FORMULA (I), WHERE Cy1 IS PHENYL OR AROMATIC HETEROCYCLE OF 5 OR 6 MEMBERS JOINED TO THE NH GROUP THROUGH A CARBON ATOM AND WHICH CAN CONTAIN FROM 1 TO 4 HETEROATOMS, OYS; Cy2 IS A MONOCYCLIC HETEROCYCLE OF 3 TO 7 MEMBERS OR BICYCLE OF 6 TO 11 MEMBERS CONTAINING 1 TO 4 HETEROATOMS SELECTED FROM N, O AND S. THE PREFERRED COMPOUNDS ARE: 2- [4- (4-MORPHOLINO) PHENYL] AMINO-4 - (PIPERIDIN-1-IL) -7H-PIRROLO [2,3-d] PYRIMIDINE, 4- (2-AZABICYCLO [2.2.1] HEPTAN-2-IL) -2- (3-FLUORO-4-METOXIFENIL) AMINO-7H-PYRROLO [2,3-d] PYRIMIDINE, (R) -2- (3-AMINOSULFONYLPHENYL) AMINO-4- (3- (N-METHYLAMINO) PYRROLIDIN-1-IL) -7H-PIRROLO [2, 3-d] PYRIMIDINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF JAK KINASE, PARTICULARLY JAK3, AND ARE USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY, NEURODEGENERATIVE, PROLIFERATIVE, AMONG OTHERS |